Challenges in Evaluating Clinical Remission in Severe Asthma: Insights from the Mayo Clinic.

Kaiser Lim¹, Arijita Deb², Thomas Corbridge³, Lydia Lee², Judy Kelloway⁴, Safak Simsek⁵, Mithun Manoharan⁵, Hannah Barman⁵, Tyler Wagner⁵

¹Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.

²Global Real-World Evidence and Health Outcomes Research, GSK, Upper Providence, PA, USA.

³Medical Affairs, GSK, 410 Blackwell Street, Durham, NC, 27701, USA. thomas.x.corbridge@gsk.com.

⁴Medical Affairs, GSK, 410 Blackwell Street, Durham, NC, 27701, USA.

⁵Nference, Cambridge, MA, USA.

PubMed PMC DOI PDF

Abstract

INTRODUCTION: Clinical remission (CR) is an ambitious and achievable treatment goal for many patients with severe asthma. This study evaluated real-life care of patients in the U.S. using CR criteria defined by the American Thoracic Society; American College of Allergy, Asthma, and Immunology; and American Academy of Allergy, Asthma & Immunology. METHODS: This retrospective cohort study (GSK ID:…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.